These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26727301)

  • 1. Heart failure in 2015: Better results from prevention than from additional treatment.
    Køber L
    Nat Rev Cardiol; 2016 Feb; 13(2):75-7. PubMed ID: 26727301
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
    Ferrari L; Sada S;
    Intern Emerg Med; 2015 Apr; 10(3):369-71. PubMed ID: 25537439
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
    Sharkey AT; Ghafar MZ; O'Keeffe ST; Mulkerrin EC
    BMJ Evid Based Med; 2019 Feb; 24(1):5-7. PubMed ID: 29991523
    [No Abstract]   [Full Text] [Related]  

  • 4. PARADIGM-HF--the experts' discussion.
    Jessup M; Fox KA; Komajda M; McMurray JJ; Packer M
    N Engl J Med; 2014 Sep; 371(11):e15. PubMed ID: 25184757
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
    Lu BN; Davis LE
    JAAPA; 2018 Jul; 31(7):35-37. PubMed ID: 29957605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.
    Ambrosy AP; Velazquez EJ
    Am Heart J; 2018 May; 199():176-177. PubMed ID: 29754658
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
    Athyros VG; Katsiki N; Karagiannis A
    Curr Vasc Pharmacol; 2014; 12(6):867-9. PubMed ID: 25516014
    [No Abstract]   [Full Text] [Related]  

  • 8. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
    Srivastava PK; Fonarow GC
    JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
    [No Abstract]   [Full Text] [Related]  

  • 9. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin Inhibitors in Cardiovascular Disease.
    Kang G; Banerjee D
    Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
    Rossignol P; Zannad F; Pitt B;
    Int J Cardiol; 2014 Dec; 177(3):731-3. PubMed ID: 25465821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 15. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of medical therapy in patients with heart failure relative to change in symptom severity.
    Ibrahim NE; Song Y; Cannon CP; Doros G; Russo P; Ponirakis A; Alexanian C; Januzzi JL
    ESC Heart Fail; 2019 Oct; 6(5):1085-1087. PubMed ID: 31268222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.